Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats

Pharmaceutical Research

Volumn 20, Issue 6, 2003, Pages 910-917

  Arimori, Kazuhiko ^a   Kuroki, Noriaki ^b   Hidaka, Muneaki ^a   Iwakiri, Tomomi ^a   Yamasaki, Keishi ^a   Okumura, Manabu ^a   Ono, Hiroshige ^a   Takamura, Norito ^a   Kikuchi, Masahiko ^c   Nakano, Masahiro ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Biliary excretion; Cyclosporin A; Intestinal exsorption; Irinotecan; P glycoprotein

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CARBOXYLIC ACID DERIVATIVE; CYCLOSPORIN A; DRUG METABOLITE; GLYCOPROTEIN P; IRINOTECAN; LACTONE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 2;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG TRANSPORT; GASTROINTESTINAL SECRETION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSCYTOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BILE; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DIGESTIVE SYSTEM; EPITHELIUM; IMMUNOSUPPRESSIVE AGENTS; LIVER; LLC-PK1 CELLS; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PERFUSION; RATS; RATS, WISTAR; SWINE; TISSUE DISTRIBUTION;

EID: 10744221722     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023847521767     Document Type: Article

References (25)

1. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effects of CPT-11. Cancer Res. 51:4187-4191 (1991).
2. A. Kojima, T. Shinkai, and N. Saijo. Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human. Jpn. J. Clin. Oncol. 23:116-122 (1993).
3. M. Narita, E. Nagai, H. Hagiwara, M. Aburada, T. Yokoi, and T. Kamataki. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23:5-10 (1993).
4. R. H. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182-2194 (2001).
5. W. Yamamoto, J. Verweiji, P. de Bruijin, M. J. de Jonge, and H. Takano, M. Nishiyama, M. Kurihara, and A. Sparreboom. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 12:419-432 (2001).
6. K. Arimori, N. Kuroki, A. Kumamoto, N. Tanoue, M. Nakano, E. Kumazawa, A. Tohgo, and M. Kikuchi. Excretion into Gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents. Pharm. Res. 18:814-822 (2001).
7. X.-Y. Chu, Y. Kato, K. Ueda, H. Suzuki, K. Niinuma, C. A. Tyson, V. Weizer, J. E. Dabbs, R. Froehlich, C. E. Green, and Y. Sugiyama. Biliary excretion mechanisms for CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 58:5137-5143 (1998).
8. E. Gupta, A. R. Safa, X. Wang, and M. J. Ratain. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res. 56:1309-1314 (1996).
9. X.-Y. Chu, Y. Kato, and Y. Sugiyama. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab. Dispos. 27:440-441 (1999).
10. M. Horikawa, Y. Kato, C. A. Tyson, and Y. Sugiyama. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metabol. Pharmacokinet. 17:23-33 (2002).
11. X.-Y. Chu, Y. Kato, K. Niinuma, K.-I. Sudo, H. Hakusui, and Y. Sugiyama. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281:304-314 (1997).
12. Y. Liu, L. Huang, T. Hoffman, M. Gosland, and M. Vore. MDR1 substrates/modulators protect against beta-estradiol- 17beta-D-glucuronide cholestasis in rat liver. Cancer Res. 56:4992-4997 (1996).
13. A. Tomimaru, K. Arimori, N. Inotsume, and M. Nakano. Effect of activated charcoal and atropine on absorption and/or exsorption of organophosphorus compounds. J. Pharm. Pharmacol. 48:351-356 (1996).
14. K. Arimori and M. Nakano. Transport of theophylline from blood to the intestinal lumen following i.v. administration to rats. J. Pharmacobio-Dyn. 8:324-327 (1985).
15. L. P. Rivory, and J. Robert. 1994. Reversed-phase high- performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. B Biomed. Appl. 661:133-141 (1994).
16. X.-Y. Chu, H. Suzuki, K. Ueda, Y. Kato, and Y. Sugiyama. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther. 288:735-741 (1999).
17. K. Ueda, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, and R. Hori. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:24248-24252 (1992).
18. F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-7738 (1987).
19. P. M. Gerk and M. Vore. Regulation of expression of the multidrug resistance-associate protein 2 (MRP2) and its role in drug disposition. J. Pharmacol. Exp. Ther. 302:407-415 (2002).
20. J. W. Smit, A. H. Schinkel, M. Muller, B. Weert, and D. K. Meijer. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27:1056-1063 (1998).
21. K. Arimori and M. Nakano. Drug exsorption from blood into the gastrointestinal tract. Pharm. Res. 15:371-376 (1998).
22. K. Akimoto, A. Kawai, and K. Ohya. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem. Pharm. Bull. 42:2135-2138 (1994).
23. Y. Sugiyama, Y. Kato, and X-X. Chu. 1998. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 42(Suppl):S44-S49 (1998).
24. X.-Y. Chu, Y. Kato, and Y. Sugiyama. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57:1934-1938 (1997).
25. K. Kobayashi, B. Bouscarel, Y, Matsuzaki, S. Ceryak, S. Kudoh, and H. Fromm. PH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int. J. Cancer 83:491-496 (1999).